Quanterix to Collaborate With the Forsyth Institute and Beth Israel Deaconess Medical Center to Develop Tuberculosis Test Feb 9, 2012 12:00PM

CAMBRIDGE, Mass., Feb. 9, 2012 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, announced today that it will apply its cutting-edge technology towards the development of an improved test to aid in the diagnosis of active tuberculosis (TB).  In collaboration with the Forsyth Institute and Beth Israel Deaconess Medical Center (BIDMC), Quanterix will validate novel low abundance protein biomarkers that may be useful for identifying individuals with active disease.  Through this strategic partnership, Quanterix will continue to expand its infectious disease applications to include ...



1,115 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All